TITLE

FDA Insists on Priority Review For VMA Drug Ocraplasmin

AUTHOR(S)
Sheridan, Cormac
PUB. DATE
February 2012
SOURCE
BioWorld Today;2/8/2012, Vol. 23 Issue 17, p3
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the decision of the U.S. Food and Drug Administration (FDA) to review the Biologics License Application (BLA) of ThromboGenics NV for its symptomatic vitreomacular adhesion (VMA) drug ocraplasmin. According to Patrik De Haes, chief executive officer (CEO) of ThromboGenics, the FDA's decision is not likely to have a major impact on the timing of the drug's approval or launch. Meanwhile, the European Medicines Agency (EMA) is also conducting review of the same drug.
ACCESSION #
71725818

 

Related Articles

  • Ocriplasmin Under the Microscope.  // BioWorld Today;7/25/2012, Vol. 23 Issue 143, p8 

    The article reports that ThromboGenic's Ocriplasmin is being assessed by the U.S. Food and Drug's Advisory Committee for possible approval.

  • EMA recommended approval for 40 new drugs in 2014. Mullard, Asher // Nature Reviews Drug Discovery;Feb2015, Vol. 14 Issue 2, p82 

    The article reports on the recommendations for drug approval on 40 new drugs by the European Medicines Agency (EMA) to the U.S. Food and Drug Administration (FDA) for treating patient's with rare diseases.

  • Belgian biotech's clot-buster approved for aging eyes. Sheridan, Cormac // Nature Biotechnology;Dec2012, Vol. 30 Issue 12, p1158 

    The article presents information on a recombinant protein drug "Jetrea," developed by ThromboGenics NV that has received the approval from the U.S. Food and Drug Administration (FDA) for the treatment of the vitreous macular adhesion (VMA). It informs that the company is also on the verge of...

  • ThromboGenics Sets January Launch as FDA Approves Jetrea. Sheridan, Cormac // BioWorld International;10/24/2012, Vol. 17 Issue 43, p1 

    This article reports on the decision of the U.S. Food and Drug Administration (FDA) to approve Jetrea (ocriplasmin), a biologic drug developed by ThromboGenics NV of Leuven, Belgium for the treatment of symptomatic vitreomacular adhesion (VMA). The company is planning to launch the product in...

  • ThromboGenics Sets January Launch as FDA Approves Jetrea. Sheridan, Cormac // BioWorld Today;10/19/2012, Vol. 23 Issue 204, p1 

    This article reports on decision of the U.S. Food and Drug Administration (FDA) to approve ThromboGeneics NV's biologic drug Jetrea (ocriplasmin) for the treatment of symptomatic vitreomacular adhesion (VMA). The company plans to commercialize the product in the U.S. starting January 2013....

  • Thrombogenics stock rises on search for sales muscle. Sheridan, Cormac // BioWorld Today;2/25/2014, Vol. 25 Issue 37, p1 

    The article reports on the 15.5 percent increase of the biopharmaceutical company Thrombogenics NV's shares concerning its plan to find a deal and buyer for the commercialization of the drug Jetrea. Information regarding the launch of drug after the U.S. Food and Drug Administration (FDA)...

  • PHARMA CONVERSATION & COMMUNITY.  // Pharmaceutical Technology;Feb2013, Vol. 25 Issue 2, p8 

    The article offers news briefs related to the pharmaceutical industry as of February 2013. The U.S. Food and Drug Administration approved 39 new molecular entities and new biologic licenses in 2012. The European Medicines Agency's (EMA) work programme for 2013 has been endorsed by the management...

  • BTG Gets 'Sentiment Boost' With Voraxaze Nod in U.S. Moran, Nuala // BioWorld Today;1/25/2012, Vol. 23 Issue 16, p2 

    The article reports on the approval of BTG PLC's Voraxaze, an antidote to the chemotherapeutic methotrexate, by the U.S. Food and Drug Administration (FDA). Following the approval, the company plans to re-engage with the European Medicines Agency after in withdrew an application for Voraxaze...

  • BTG Gets 'Sentiment Boost' With Voraxaze Nod in U.S. Moran, Nuala // BioWorld International;1/25/2012, Vol. 17 Issue 4, p2 

    The article reports on the approval awarded by the U.S. Food and Drug Administration (FDA) to Voraxaze, an antidote to the chemotherapeutic methotrexate from BTG PLC. Andy Burrows, the director of investor relations at BTG, admits that the FDA approval is a sentiment boost. Due to the FDA...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics